Future Revenue Drivers
CAR T-cell therapies are projected to be among the highest revenue drivers in the gene therapy class in 2028 with large pharma topping the list. The multiple myeloma market is expected to see significant revenue, including $4.7B from J&J’s Carvytki and BMS’ Abecma also a key contributor. Non-Hodgkin’s lymphoma is also expected to be a key disease area with $2.4bn and $640m forecasted from Gilead’s Yescarta and Tecartus, respectively, and $1.9bn from BMS’ Breyanzi.
Outside of CAR T-cells and oncology, gene targeting therapies are also expected to be key revenue drivers in 2028. Duchenne’s muscular dystrophy treatments Elevidys and PF-06939926 (both dystrophin gene targeting) are forecasted to return just over $3bn for Sarepta and its partner Roche, and $383M for Pfizer, respectively. Novartis’ currently available treatment Zolgensma (survival motor neurone gene) has $1.7bn projected for spinal muscular atrophy, while Krystal Biotech’s Vyjuvek for epidermolysis bullosa is expected to pull in $643m.$515m for Rocket Pharmaceutical’s RP-A501 (lysosome-associated membrane glycoprotein 2 gene transference) in cardiovascular disease. Haematology seems to be a popular therapy area with $971m expected for BioMarin’s Roctavian in haemophilia A, and $412m for Rocket’s RP-L102 (FA complementation group A GENE) for anaemia.
Non genetically-modified cell therapies, particularly T-cells and stem cells, are expected to generate significant revenue in 2028 for smaller players. Iovance Biotherapeutics, a Dutch-based biotech with its HQ in the US, has two anti-PD-1, tumour-infiltrating lymphocyte (TIL) T-cell therapies Amtagvi, approved for melanoma and LN-145, in Phase 2 for cervical cancer and NSCLC, which are expected to generate $572m and $387m, respectively. Another T-cell therapy, commercial-stage biotech’s Immunocore’s IMC-F106C, that targets a specific antigen associated with melanoma, preferentially expressed antigen of melanoma (PRAME), is expected to yield $313m for melanoma. Mesenchymal stem cells are expected to be large revenue drivers for Mesoblast with Revascor and MPC-06-D and Ryoncil expected to yield a total of just over $1bn for coronary heart failure, lower back pain and graft-vs-host disease, respectively. Brainstorm also has NurOwn, a mesenchymal bone marrow stromal stem cell therapy for amyotrophic lateral sclerosis and primary-progressive multiple sclerosis, forecasted to generate around $350m.